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Epidermolysis bullosa (EB) is a group of heritable mechano-
bullous disorders characterized by fragility of the skin within
the cutaneous basement membrane zone (BMZ) (Fine et al,
2000). The severity of skin manifestations can be highly
variable, so that in one end of the spectrum the skin findings
may be relatively minor blistering tendency primarily on the
hands and feet, whereas at the other end of the spectrum
the compromised integrity of skin can result in early post-
natal demise of the affected individual. Prior to identification
of the gene/protein systems harboring mutations in different
variants of EB, this phenotypic variability was quite puz-
zling, compounded by the fact that there are a number of
extracutaneous manifestations associated with the skin
findings. This phenotypic complexity, coupled with classi-
fications riddled with eponyms, has led to a suggestion that
there are  30 different subtypes of EB (Anton-Lamprecht
and Gedde-Dahl, 2002).1
Traditionally, EB has been divided into three broad cat-
egories: (a) the simplex forms demonstrate tissue separa-
tion within the basal keratinocytes; (b) the junctional forms
depict tissue separation within the lamina lucida of the der-
mal–epidermal basement membrane; and (c) the dystrophic
forms show tissue cleavage below the lamina densa within
the upper papillary dermis (Fig 1). We have recently pro-
posed a fourth subtype, the hemidesmosomal variants of
EB, in which the tissue separation is at the basal cell/lamina
lucida interface at the level of hemidesmosomes (Fig 1)
(Pulkkinen and Uitto, 1998). In fact, the hemidesmosomal
variants include the following clinical entities: (a) General-
ized atrophic benign EB (GABEB) that has been previously
included in the category of non-Herlitz junctional EB (JEB);
(b) EB with pyloric atresia where tissue separation is either
just outside of the plasma membrane of the basal cells or in
the low intracellular compartment and has occasionally
been referred as ‘‘pseudo-junctional’’ EB; (c) EB with mus-
cular dystrophy which shows low intracellular cytolysis
occasionally suggested to belong to the simplex category of
EB (Pulkkinen and Uitto, 1998).
With the advent of molecular genetics in general and
essential completion of the human genome project, specific
mutations have now been identified in ten distinct genes
expressed within the cutaneous BMZ (Table I)2 (Uitto et al,
2002). The compartmentalized expression of these genes
within the cutaneous BMZ, the types and combinations of
the mutations, and their consequences at the mRNA and
protein levels, when superimposed on the individuals’ ge-
netic background and combined with environmental fac-
tors, explain the spectrum of severity in EB.
Considerable clinical and molecular heterogeneity is rec-
ognized particularly in the JEB, which has been traditionally
divided into Herlitz (lethal) and non-Herlitz variants depend-
ing on the severity and outcome of the disease. Specifically,
most children with the Herlitz variant die within the first year
of life, whereas non-Herlitz patients have life-long blistering
but their lifespan is not significantly compromised. The Her-
litz JEB is due to absence of laminin 5, and mutations have
been identified in three genes (LAMA3, LAMB3, and LAM-
C2), which encode the subunit polypeptides a3, b3, and g2
of laminin 5, respectively. Most of these mutations result in
premature termination codon for translation (PTC) (Nakano
et al, 2000). In non-Herlitz variants, missense mutations
have been identified also in the laminin 5 genes, but in
addition, mutations can reside in the 180 kDa bullous
pemphigoid antigen/type XVII collagen gene, BPAG2/
COL17A1 (Nakano et al, 2002).
In this issue, Posteraro et al (2004) have analyzed an
Italian cohort of 19 patients with JEB, 11 being affected with
the severe Herlitz type and eight with milder non-Herlitz
type. The authors concentrated their analysis on LAMA3,
LAMB3, and LAMC2 and identified 18 mutations, seven of
which were previously unpublished. In accordance with
previous observations, PTC mutations in both alleles of the
laminin 5 genes were predominant in Herlitz JEB patients,
whereas splicing or missense mutations resulting in re-
duced synthesis of partially functional laminin 5 were pre-
dominantly found in non-Herlitz variants. The authors
also disclosed a number of recurrent mutations, including
R635X in the LAMB3 gene, a mutation frequent in Cauca-
sian Herlitz JEB patients, particularly in Northern European
Abbreviations: BMZ, basement membrane zone; EB, epidermo-
lysis bullosa; JEB, junctional EB
1Dermatologists are ‘‘often characterized as lumpers or split-
ters. For one perspective, splitters recognize more species than
really exist, and lumpers go around fixing the resulting damage’’
(Gary Rosenberg) (Cited in Novelli and D’Apice, Trends Mol Med
9:370, 2003).
2DebRA Molecular Diagnostics Laboratory, a CLIA-Certified
Molecular Testing Laboratory established in 1996 as a partnership
of the Dystrophic Epidermolysis Bullosa Research Association of
America and the Department of Dermatology and Cutaneous Bi-
ology at Jefferson Medical College, has analyzed as of today over
1000 families with different forms of EB for mutations, including
over 300 families with junctional forms. Among these families, a
total of 689 distinct mutations in the 10 genes underlying the major
forms of EB have been disclosed. It should be noted that this
number does not count homozygous mutations twice or recurrent
mutations multiple times. Thus, there is a large number of private,
family-specific mutations in EB.
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countries. Of particular interest in the study of Posteraro
et al was a case in which a homozygous deletion mutation
(1587delAG) in exon 13 is predicted to lead to a frameshift
and formation of a downstream premature termination co-
don in exon 14 of the LAMB3 gene and is, therefore, ex-
pected to have severe Herlitz JEB phenotype. The patient,
however, had a relatively mild, non-Herlitz JEB clinical pres-
entation, and immunoreactive laminin 5 was detected along
the dermal–epidermal junction, although in reduced quan-
tities. Analysis of the corresponding mRNA by RT-PCR and
northern analysis revealed a transcript in which the entire
exon 14 was deleted, restoring the reading frame and thus
resulting in synthesis and secretion of a shortened b3 po-
lypeptide. This polypeptide was apparently stable, allowed
synthesis of some laminin 5 protein, and explained the rel-
atively mild phenotype in this patient. Finally, the authors
showed a large intragenic duplication in the LAMC2 gene, a
type of mutation that has not been previously identified in
JEB patients. Collectively, the data provided by Posteraro
et al add to the existing database on JEB mutations and
provide new insight into the molecular mechanisms leading
to skin fragility in these patients.
Considering the fact that over 1000 families with different
variants of EB, including some 300 families with JEB, have
been analyzed for mutations, a reasonable question is why
to analyze additional patients for mutations. Or more broad-
ly, what are the implications, if any, of molecular genetics on
diagnosis and management of patients with EB? It is very
clear that advances in molecular diagnostics have had a
major impact on understanding the pathomechanisms and
clinical features of EB. Identification of specific mutations
has also improved diagnosis and has provided a basis
for molecularly based classification with prognostic impli-
cations (Table I). Furthermore, identification of specific mu-
tations in families can assist in providing accurate genetic
counseling regarding the risk of recurrence of EB in
the same and subsequent generations in cases where the
mode of inheritance cannot be readily deciphered from
the family constellation. Perhaps most importantly, identi-
fication of mutations has formed the basis for DNA-based
prenatal testing for families at risk for recurrence of EB
(Pfendner et al, 2003). In case of junctional forms of EB,
prenatal testing, which can be performed through chorionic
villus sampling as early as the tenth week gestation, has
to be based on specific mutations since genetic lesions
in any of the three laminin 5 subunit genes, LAMA3, LAMB3,
or LAMC2, can result in a phenocopy. The same require-
ments are applicable to early prenatal diagnosis through
preimplantation genetic diagnosis or application of non-
invasive mutation analysis from fetal DNA in maternal
blood (Uitto et al, 2003).
DOI: 10.1111/j.0022-202X.2004.23333.x
References
Anton-Lamprecht I, Gedde-Dahl T: Epidermolysis bullosa. In: Rimoin D, et al:
(eds). Principles and Practice of Medical Genetics, 4th edn. London:
Churchill-Livingstone, 2002; p 3810–3897
Fine J-D, Eady RAJ, Bauer EA, et al: Revised classification system for inherited
epidermolysis bullosa: Report of the second international consensus
meeting on diagnosis and classification of epidermolysis bullosa. J Am
Acad Dermatol 42:1051–1066, 2000
Koss-Harnes D, Hoyheim B, Anton-Lamprecht I, et al: A site-specific plectin
mutation causes dominant epidermolysis bullosa simplex Ogna: Two
identical de novo mutations. J Invest Dermatol 118:87–93, 2002
Nakano A, Chao S-C, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfendner E,
Uitto J: Laminin 5 mutations in junctional epidermolysis bullosa: Molec-
ular basis of Herlitz vs. non-Herlitz phenotypes. Hum Genet 110:41–51,
2002
Nakano A, Pfendner E, Pulkkinen L, Hashimoto I, Uitto J: Herlitz junctional
epidermolysis bullosa: Novel and recurrent mutations in the LAMB3 gene
and the population carrier frequency. J Invest Dermatol 115:493–498,
2000
Pfendner E, Nakano A, Pulkkinen L, Christiano AM, Uitto J: Prenatal diagnosis for
epidermolysis bullosa: A study of 144 consecutive pregnancies at risk.
Prenat Diag 23:447–456, 2003
Posteraro P, De Luca N, Meneguzzi G, et al: Laminin-5 mutational analysis in an
Italian cohort of patients with junctional epidermolysis bullosa. J Invest
Dermatol 123:639–648, 2004
Pulkkinen L, Uitto J: Hemidesmosomal variants of epidermolysis bullosa. Muta-
tions in the a6b4 integrin and the 180-kD bullous pemphigoid antigen/
type XVII collagen genes. Exp Derm 7:46–64, 1998
Uitto J, Pfendner E, Jackson LG: Probing the fetal genome: Progress towards
non-invasive prenatal diagnosis. Trends Mol Med 9:339–343, 2003
Uitto J, Pulkkinen L, Ringpfeil F: Progress in molecular genetics of heritable skin
diseases: The paradigms of EB and PXE. J Invest Dermatol Symp Proc
7:6–16, 2002
Figure 1
Schematic representation of the cutaneous basement membrane
zone. On the right, the approximate levels of tissue separation in four
different variants of epidermolysis bullosa (EB) are indicated.
Table I. Molecular classiﬁcation of epidermolysis bullosa
Category Level of blistering Mutated genes
Simplex Basal cells KRT5, KRT14
Hemidesmosomal Basal cell/LL
interface
GABEB BPAG2/COL17A1
EB-PA ITGB4, ITGA6
EB-MD PLEC1a
Junctional Lamina lucida LAMA3, LAMB3,
LAMC2
Dystrophic Sublamina densa COL7A1
GABEB, generalized atrophic benign EB; EB-PA, EB with pyloric
atresia; EB-MD, EB with late-onset muscular dystrophy; LL, lamina
lucida.
aPlectin mutations have also been disclosed in the Ogna variant of EB
simplex (Koss-Harnes et al, 2002).
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